Brazil's R&D-based industry outlines priorities for new president
This article was originally published in SRA
With Brazil's new president, Dilma Rousseff, to be inaugurated in January, the pharmaceutical industry has a list of issues that it would like the government to tackle. Greater pricing freedom and reducing the time it takes to grant a patent are just two priorities, explains Jorge Raimundo, president of the advisory council of Interfarma, Brazil's R&D-based industry association1.
You may also be interested in...
Industry access to real world data for regulatory and market access purposes in Asia Pacific compares poorly with the US.
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in a move towards increasing biosimilar uptake.